Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating type 2 diabetes mellitus and preparation method of pharmaceutical composition

A technology for type 2 diabetes and composition, applied in the directions of drug combination, pharmaceutical formula, active ingredient of hydroxyl compound, etc., to avoid subcutaneous fat accumulation, eliminate side effects, and promote digestion

Inactive Publication Date: 2020-11-20
陈爱红
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, the combination of triptolide, triptolide alkaloids and Ligustrum mannitol for the prevention and treatment of diabetic nephropathy has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating type 2 diabetes mellitus and preparation method of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] This embodiment relates to a pharmaceutical composition for the treatment of type 2 diabetes, a pharmaceutical composition for the treatment of type 2 diabetes, comprising the following components in parts by weight: 3 parts of black plum, 5 parts of Chinese yam, 3 parts of Ganoderma lucidum 2 parts of reed root, 2 parts of Imperata rhizome, 2 parts of roasted licorice, 2 parts of Ophiopogon japonicus, 4 parts of Anemarrhena, 0.5 parts of Ligustrum mannitol, 2 parts of zinc sulfate, 2 parts of broiled astragalus, 5 parts of Polygonatum, Poria cocos 6 servings.

Embodiment 2

[0065] This embodiment relates to a pharmaceutical composition for treating type 2 diabetes. This embodiment relates to a pharmaceutical composition for treating type 2 diabetes, including the following components in parts by weight: 18 parts of black plum, 10 parts of Chinese yam 10 parts of Ganoderma lucidum, 18 parts of reed root, 18 parts of Imperata rhizome, 8 parts of roasted licorice, 9 parts of Ophiopogon japonicus, 15 parts of Anemarrhena, 3 parts of Ligustrum mannitol, 5 parts of zinc sulfate, 18 parts of broiled astragalus, sealwort 12 parts, Poria cocos 12 parts.

Embodiment 3

[0067] This embodiment relates to a pharmaceutical composition for treating type 2 diabetes. This embodiment relates to a pharmaceutical composition for treating type 2 diabetes, including the following components in parts by weight: 3 parts of black plum, 5 parts of Chinese yam 3 parts of Ganoderma lucidum, 2 parts of reed root, 2 parts of Imperata rhizome, 2 parts of roasted licorice, 2 parts of Ophiopogon japonicus, 4 parts of Anemarrhena, 0.5 parts of Ligustrum lucidum mannitol, 2 parts of zinc sulfate, 2 parts of roasted astragalus, sealwort 5 parts, Poria cocos 6 parts, triptolide 0.2 parts, triptolide alkaloid 1.2 parts.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating type 2 diabetes mellitus. The pharmaceutical composition comprises the following components in parts by weight: 3-18 parts of dark plum fruits, 5-10 parts of yam, 3-10 parts of ganoderma lucidum, 2-18 parts of reed rhizomes, 2-18 parts of lalang grass rhizomes, 2-8 parts of honey-fried licorice roots, 2-9 parts of dwarf lilyturf tubers, 4-15 parts of rhizoma anemarrhenae, 0.5-3 parts of glossy privet fruit mannitol, 2-5 parts of zinc sulfate, 2-18 parts of radix astragali preparata, 5-12 parts of rhizoma polygonati and 6-12 parts of poria cocos. The pharmaceutical composition has the beneficial effects that the pharmaceutical composition has significant adjuvant therapy effects on the type 2 diabetes mellitus and can stabilize the blood glucose of a patient, besides, the fasting blood-glucose efficiency and postprandial blood glucose efficiency change in a range of + / -5%, and the side effects are small.

Description

technical field [0001] The invention belongs to the technical field of natural medicines, in particular to a pharmaceutical composition for treating type 2 diabetes. Background technique [0002] Western medicine believes that diabetes is a chronic metabolic disease caused by genetic factors and environmental factors. Disorder, a disease that has a significant impact on the lives of patients. [0003] Diabetes is called diabetes in traditional Chinese medicine, and it is believed that it is due to congenital deficiency of limbs, weak viscera, addiction to fat, sweet, thick food, wine and cheese, accumulation of heat and tendons, long-term depression of emotions, heat and yin, excessive sexual labor, and loss of kidney essence , Sedentary and less active, physical weakness, disorderly taking warm and dry medicines and depleting yin and fluid caused by the disease. [0004] Currently, there is no cure for type Ⅰ and type Ⅱ diabetes. Therefore, the main methods of comprehens...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/899A61P3/10A61K31/047A61K33/30A61K31/585
CPCA61K31/047A61K31/585A61K33/30A61K36/074A61K36/076A61K36/37A61K36/481A61K36/484A61K36/638A61K36/736A61K36/8945A61K36/8964A61K36/8968A61K36/8969A61K36/899A61K2236/331A61K2236/39A61K2236/51A61K2236/53A61P3/10A61K2300/00
Inventor 陈爱红
Owner 陈爱红
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com